Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical trials with sigma ligands.

H-P Volz1, K D Stoll

  • 1Krankenhaus für Psychiatrie und Psychotherapie Schloss Werneck, Balthasar-Neumann-Platz 1, D-97440 Werneck, Germany. hans-peter-volz@kh-schloss-werneck.de

Pharmacopsychiatry
|November 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Pain and sleep disturbances].

MMW Fortschritte der Medizin·2016
Same author

[Therapeutic effects of venlafaxine extended release for patients with depressive and anxiety disorders in the German outpatient setting - results of 2 observational studies including 8500 patients].

Fortschritte der Neurologie-Psychiatrie·2009
Same author

[Cognitive disorders in schizophrenic patients].

Der Nervenarzt·2009
Same author

[Diagnosis and treatment of anxiety disorders].

MMW Fortschritte der Medizin·2008
Same author

Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective.

Current medical research and opinion·2008
Same author

31P-MR spectroscopy in children and adolescents with a familial risk of schizophrenia.

European radiology·2003
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
Same journal

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
See all related articles

Sigma receptor ligands like igmesine and siramisine show potential for functional diarrhea, depression, and anxiety. Opipramol

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Sigma ligands have been explored for various central nervous system disorders.
  • Previous investigations targeted functional diarrhea, depression, anxiety, schizophrenia, and somatoform disorders.

Purpose of the Study:

  • To review the therapeutic potential of sigma ligands.
  • To evaluate the clinical efficacy of specific sigma ligands, including igmesine, siramisine, and opipramol.

Main Methods:

  • Review of human and animal studies involving sigma ligands.
  • Analysis of pharmacological profiles and clinical outcomes.

Main Results:

  • Igmesine demonstrated efficacy in functional diarrhea and depression models, but development ceased.

Related Experiment Videos

  • Siramisine showed anxiolytic properties but was discontinued.
  • Opipramol exhibited broad efficacy in generalized anxiety and somatoform disorders, acting via sigma receptors.

    • Conclusions:

    • Opipramol's efficacy in anxiety and somatoform disorders may be mediated through sigma receptor activity.
    • Despite promising preclinical data, marketing and development issues have halted progress for some selective sigma ligands.